<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Antibodies were not used	n/a

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	Cell materials were not used	n/a
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	Cell materials were not used	n/a

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	Experimental animals were not used	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible	Experimental animals were not used	n/a
Model organisms: Provide Accession number in repository (where relevant) OR RRID		n/a

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	Plants and microbes were not used	n/a
Microbes: provide species and strain, unique accession number if available, and source	Plants and microbes were not used	n/a

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Ethical Statement /paragraph 1	
Provide statement confirming informed consent obtained from study participants.	Ethical Statement /paragraph 1	
Report on age and sex for all study participants.	Result/paragraph 1	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	It was a cross-sectional study of previous data	n/a
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	Methods/ Clinical specimens/ paragraph 1	n/a
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		n/a
Sample size determination	Results/paragraph 1	
Randomisation	It was a cross-sectional study of previous data	n/a
Blinding	It was a cross-sectional study of previous data	n/a
Inclusion/exclusion criteria	It was a cross-sectional study of previous data	n/a
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory		n/a
Define whether data describe technical or biological replicates		n/a
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Ethical Statement /paragraph 1	.,, -
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Experimental animals were not used	n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Methods/ Clinical specimens /paragraph 1 Ethical Statement /paragraph 1	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		n/a

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is		
excluded, and whether the criteria for exclusion were	Methods/ Clinical specimens /paragraph 1	
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a	
Describe statistical tests used and justify choice of	Methods/ Statistical analysis /paragraph 1		Ì
tests.	iviethous/ Statistical analysis / paragraph 1	1	l

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	The data was collected at 3DMed Clinical Laboratory Inc	n/a
If data are publicly available, provide accession number in repository or DOI or URL.	The data was collected at 3DMed Clinical Laboratory Inc	n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	The data was collected at 3DMed Clinical Laboratory Inc	n/a

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		- /-
for replicating the main findings of the study:		n/a
State whether the code or software is available.	Methods/ Statistical analysis /paragraph 1	n/a
If code is publicly available, provide accession	The code was not used	2/2
number in repository, or DOI or URL.	The code was not used	n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

 $Article\ information:\ \underline{https://dx.doi.org/10.21037/atm-22-3162}$